Although most FDA-approved anti-angiogenic drugs for cancer treatment are VEGFA/VEGFR2 inhibitors, these inhibitors can lead to development of resistances or increased tumour aggressiveness in patients [6,7]. This evidence concerns the gene VEGFA and neoplasm.